Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alzamend Neuro Inc (ALZN)

Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,249
  • Shares Outstanding, K 3,802
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,510 K
  • EBIT $ -6 M
  • EBITDA $ -6 M
  • 60-Month Beta -0.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 01/31/26
See More
  • Average Estimate -0.80
  • Number of Estimates 1
  • High Estimate -0.80
  • Low Estimate -0.80
  • Prior Year -1.71
  • Growth Rate Est. (year over year) +53.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.88 +12.23%
on 11/24/25
2.56 -17.58%
on 11/19/25
-0.11 (-4.95%)
since 11/14/25
3-Month
1.88 +12.23%
on 11/24/25
2.68 -21.27%
on 10/31/25
-0.24 (-10.21%)
since 09/15/25
52-Week
1.88 +12.23%
on 11/24/25
12.06 -82.50%
on 12/16/24
-8.60 (-80.30%)
since 12/13/24

Most Recent Stories

More News
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

ATLANTA , Nov. 19, 2025 /PRNewswire/ --  Alzamend Neuro, Inc. (Nasdaq: ALZN) (" Alzamend "), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment...

ALZN : 2.11 (-2.76%)
Alzamend Neuro Issues New Common Stock Shares

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alzamend...

ALZN : 2.11 (-2.76%)
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, and Programs Presentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in...

ALZN : 2.11 (-2.76%)
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

During the year ended April 30, 2025, net cash provided by financing activities was $10.4 million Stockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cash In May 2025,...

ALZN : 2.11 (-2.76%)
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

ALZN : 2.11 (-2.76%)
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

ALZN : 2.11 (-2.76%)
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

ALZN : 2.11 (-2.76%)
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

ALZN : 2.11 (-2.76%)
Alzamend Neuro Announces Reverse Stock Split

ALZN : 2.11 (-2.76%)
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

ALZN : 2.11 (-2.76%)

Business Summary

Alzamed Neuro is an early clinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline...

See More

Key Turning Points

3rd Resistance Point 2.21
2nd Resistance Point 2.19
1st Resistance Point 2.15
Last Price 2.11
1st Support Level 2.09
2nd Support Level 2.07
3rd Support Level 2.03

See More

52-Week High 12.06
Fibonacci 61.8% 8.17
Fibonacci 50% 6.97
Fibonacci 38.2% 5.77
Last Price 2.11
52-Week Low 1.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar